Cover Image

Secukinumab: Rapid Efficacy in Psoriasis After Primary Failure With Ustekinumab and Adalimumab

Saved in:

Bibliographic Details
Main Authors:	Aline Lissa Okita (Author), Tatiane Benini (Author), Denise Reis Longhi (Author)
Format:	Book
Published:	Mattioli1885, 2020-10-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Ustekinumab successfully treated a patient with severe psoriasis vulgaris with primary failure to infliximab and secondary failure to adalimumab
by: Chiharu Tateishi, et al.
Published: (2015)

Efficacy and safety of cyclosporin, adalimumab and secukinumab in the treatment of nail psoriasis
by: Zhanhan TANG, et al.
Published: (2023)

Adalimumab, Ustekinumab, and Secukinumab in the Management of Hidradenitis Suppurativa: A Review of the Real-Life Experience
by: Martora F, et al.
Published: (2023)

Comparision of the efficacy and safety between Secukinumab and Adalimumab in the treatment of the moderate to severe plaque psoriasis
by: Dandan HU, et al.
Published: (2023)

Pyoderma gangrenosum induced by secukinumab in a patient with psoriasis successfully treated with ustekinumab
by: Amy J. Petty, BS, et al.
Published: (2020)

Secukinumab in psoriasis patients with prior ustekinumab treatment: Results of a single-center experience
by: Ting-Shun Wang, et al.
Published: (2017)

Long-Term Psoriasis Control with Guselkumab, Adalimumab, Secukinumab, or Ixekizumab in the USA
by: Timothy Fitzgerald, et al.
Published: (2023)

Steps towards implementation of protocolized dose reduction of adalimumab, etanercept and ustekinumab for psoriasis in daily practice
by: L.S. van der Schoot, et al.
Published: (2023)

Secukinumab is Superior to Ustekinumab in Clearing Skin in Patients with Moderate to Severe Plaque Psoriasis (16-Week CLARITY Results)
by: Jerry Bagel, et al.
Published: (2018)

Comparative Efficacy and Safety of Ustekinumab and Secukinumab in the Treatment of Generalized Pustular Psoriasis: A 48-Week Retrospective Cohort Study with Genetic Background Analysis
by: Ruan SF, et al.
Published: (2024)

Response to the Letter to the Editor: Long-Term Psoriasis Control with Guselkumab, Adalimumab, Secukinumab, or Ixekizumab in the USA
by: Timothy Fitzgerald, et al.
Published: (2023)

Evaluation of a One-step Dose Reduction Strategy of Adalimumab, Etanercept and Ustekinumab in Patients with Psoriasis in Daily Practice
by: Selma Atalay, et al.
Published: (2021)

Routine Laboratory Parameter Dynamics and Laboratory Adverse Events in Psoriasis Patients on Long-term Treatment with Adalimumab, Etanercept, and Ustekinumab
by: Jochen H. Hoffmann, et al.
Published: (2017)

Adherence to treatment with adalimumab, golimumab and ustekinumab in patients with inflammatory bowel disease
by: María Calvo-Arbeloa, et al.
Published: (2020)

Ustekinumab: differential use in psoriasis
by: Uhlenhake EE, et al.
Published: (2011)

Letter to the Editor: Response to Fitzgerald T et al. Long-Term Psoriasis Control with Guselkumab, Adalimumab, Secukinumab, or Ixekizumab in the USA
by: Andrew Blauvelt, et al.
Published: (2023)

Efficacy and Safety of Secukinumab in Patients with Plaque Psoriasis and Latent Tuberculosis
by: Simone Ribero, et al.
Published: (2019)

Thyrotoxicosis Associated with Ustekinumab Treatment for Psoriasis
by: Bayanne Olabi, et al.
Published: (2020)

Secukinumab in generalized pustular psoriasis
by: Shraddha Madanagobalane
Published: (2018)

Secukinumab Therapy in Psoriasis Management
by: Ira Yunita, et al.
Published: (2022)

Efficacy and safety evaluations of adalimumab biosimilars in the treatment of psoriasis
by: Changkun Li, et al.
Published: (2023)

Description of the Clinical Case of Adalimumab and Secukinumab Therapy of a Patient with Psoriatic Arthritis
by: V. V. Didenko, et al.
Published: (2021)

Peritoneal tuberculosis in the setting of ustekinumab treatment for psoriasis
by: Maeve Lynch, MD, MBBChBAO, et al.
Published: (2017)

Meta-analysis of efficacy and safety of adalimumab injection for arthropathic psoriasis
by: Nan LI, et al.
Published: (2019)

The significance of secukinumab in the treatment of plaque psoriasis
by: Marta Kasprowicz-Furmańczyk, et al.
Published: (2022)

Efficacy of Secukinumab in Psoriasis: Post Hoc Gender-Wise Analysis of the SUPREME Study
by: Stingeni L, et al.
Published: (2023)

A case report of heart failure after therapy with ustekinumab
by: Kourosh Beroukhim, et al.
Published: (2015)

Efficacy and safety of ustekinumab in adolescents
by: Kellen R, et al.
Published: (2016)

Emerging treatments in the management of psoriasis: biological targeting with ustekinumab
by: Marina Papoutsaki, et al.
Published: (2009)

Is anti‐IL‐17 faster and anti‐IL‐23 better for psoriasis patients after adalimumab failure?
by: Xiaojun Shi, et al.
Published: (2024)

Identification immune response genes in psoriasis after treatment with secukinumab
by: Jing Wang, et al.
Published: (2023)

Efficacy of Adalimumab for Nail Psoriasis During 24 Months of Continuous Therapy
by: Georgios Kokolakis, et al.
Published: (2020)

Ustekinumab Efficacy and Safety in Children with Plaque, Erythrodermic and Palmoplanar Forms of Psoriasis: Retrospective Cohort Study
by: Nikolay N. Murashkin, et al.
Published: (2020)

Ustekinumab treats psoriasis by suppressing RORC and T-box but its suppression of GATA restrains its efficacy
by: Lun-Fei Liu, et al.
Published: (2019)

Secukinumab in the Treatment of Plaque Psoriasis in Patients with Malignancy
by: Alessio Gambardella
Published: (2019)

Secukinumab in psoriasis: A single-center experience
by: Esra Ağaoğlu, et al.
Published: (2021)

Secukinumab-induced paradoxical palmoplantar pustular psoriasis
by: Yıldız Gürsel Ürün, et al.
Published: (2022)

Secukinumab in the treatment of psoriasis: patient selection and perspectives
by: Yang EJ, et al.
Published: (2018)

Promising results with secukinumab in refractory pediatric psoriasis
by: Sukriti Baveja, et al.
Published: (2020)

Profile of secukinumab in the treatment of psoriasis: current perspectives
by: Roman M, et al.
Published: (2015)